Drugs / denovoSkin(TM)
last change Jul 2026 re-read 3 minutes ago

denovoSkin(TM)

Cell therapy

Investigated by
CUTISS AG · RCTs

Trials 1

202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT06745557 Dec 2024 → Dec 2026 expected — CUTISS AG Recruiting No outcome recorded

Press releases naming this drug 25 releases

DateIssuerRelease
2026-07-26 CUTISS AG Rai 1’s Noos: inside CUTISS and the making of denovoSkin™ cutiss.swiss ↗
2026-03-31 CUTISS AG New publication reports 1-year phase II results for denovoSkin™ in reconstructive surgery cutiss.swiss ↗
2026-03-17 CUTISS AG New publication reports U.S. compassionate use of denovoSkin™ in pediatric reconstructive surgery cutiss.swiss ↗
2025-12-02 CUTISS AG denovoSkin™ positive safety & efficacy 1-year readout in Phase 2 trial for adolescent and adult burn patients cutiss.swiss ↗
2025-05-27 CUTISS AG Positive Phase 2 trial interim analysis on safety and efficacy for denovoSkin™ in pediatric burn patients cutiss.swiss ↗
2025-05-20 CUTISS AG Case report: denovoSkin™ used under compassionate use in pediatric reconstructive burn surgery cutiss.swiss ↗
2025-05-06 CUTISS AG CUTISS advances Phase 3 clinical trial of denovoSkin™ cutiss.swiss ↗
2025-02-12 CUTISS AG Positive Phase 2 trial readout for long-term efficacy & safety of denovoSkin™ in reconstructive skin surgery and in burns cutiss.swiss ↗
2024-12-03 CUTISS AG EMA authorizes Phase 3 clinical trial for denovoSkin™ cutiss.swiss ↗
2024-10-11 CUTISS AG The Boston Globe reports on first U.S. patient treated with denovoSkin™ cutiss.swiss ↗
2024-07-09 CUTISS AG Reconstructive skin surgery: positive Phase 2 interim analysis on efficacy for denovoSkin™ in pediatric, adolescent and adult patients cutiss.swiss ↗
2024-05-06 CUTISS AG La Repubblica: denovoSkin™ applied in pediatric burns in Milano cutiss.swiss ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as denovoSkin(TM) ClinicalTrials.gov intervention name — accepted as the source's own label NCT06745557 ↗
Modality Cell therapy “a Bilayer Engineered Collagen-based Skin Graft Composed of Autologous Fibroblasts and Keratinocytes” NCT06745557 ↗